What Is the Biological and Clinical Relevance of Fibrin?
暂无分享,去创建一个
[1] D. Witte,et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin αMβ2 binding motif , 2007 .
[2] D. Witte,et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. , 2007, The Journal of clinical investigation.
[3] Max Potters,et al. Structural hierarchy governs fibrin gel mechanics. , 2010, Biophysical journal.
[4] J. Frampton,et al. Thrombin‐induced conversion of fibrinogen to fibrin results in rapid platelet trapping which is not dependent on platelet activation or GPIb , 2003, British journal of pharmacology.
[5] N. Killeen,et al. Integrin cytoplasmic tyrosine motif is required for outside-in αIIbβ3 signalling and platelet function , 1999, Nature.
[6] J. Melero-Martin,et al. Type I collagen, fibrin and PuraMatrix matrices provide permissive environments for human endothelial and mesenchymal progenitor cells to form neovascular networks , 2011, Journal of Tissue Engineering and Regenerative Medicine.
[7] W. Schobersberger,et al. Time for changing coagulation management in trauma-related massive bleeding , 2009, Current opinion in anaesthesiology.
[8] J. Forrester. Malpighi's De polypo cordis: an annotated translation. , 1995, Medical history.
[9] S. E. James,et al. A review of tissue-engineered skin bioconstructs available for skin reconstruction , 2010, Journal of The Royal Society Interface.
[10] P. Janmey,et al. Fibrin gels and their clinical and bioengineering applications , 2009, Journal of The Royal Society Interface.
[11] G. Kovacs,et al. Evaluation of D-Dimer in the diagnosis of suspected deep-vein thrombosis , 2004 .
[12] Y. Sakata,et al. A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. , 2002, Clinica chimica acta; international journal of clinical chemistry.
[13] M. Carr. Development of platelet contractile force as a research and clinical measure of platelet function , 2007, Cell Biochemistry and Biophysics.
[14] T. Haas,et al. The effect of fibrinogen concentrate on thrombocytopenia , 2007, Journal of thrombosis and haemostasis : JTH.
[15] W. Tracz,et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. , 2009, Blood.
[16] Chengyu Liu,et al. Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. , 2012, Blood.
[17] J. Bennett,et al. Platelet‐Fibrinogen Interactions , 2001, Annals of the New York Academy of Sciences.
[18] John J. Foxe,et al. Towards obtaining spatiotemporally precise responses to continuous sensory stimuli in humans: A general linear modeling approach to EEG , 2014, NeuroImage.
[19] S. Hsiao,et al. Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth. , 2008, Blood.
[20] K. Gutkowski,et al. Coagulopathy in liver diseases. , 2010, Advances in medical sciences.
[21] A. Undas. How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice? , 2016, Seminars in Thrombosis & Hemostasis.
[22] M. Flick,et al. Fibrinogen Is at the Interface of Host Defense and Pathogen Virulence in Staphylococcus aureus Infection , 2016, Seminars in Thrombosis & Hemostasis.
[23] Dennis E. Discher,et al. Multiscale Mechanics of Fibrin Polymer: Gel Stretching with Protein Unfolding and Loss of Water , 2009, Science.
[24] R. Lassila. Clinical Use of Factor XIII Concentrates , 2016, Seminars in Thrombosis & Hemostasis.
[25] J. Weisel,et al. Composition of coronary thrombus in acute myocardial infarction. , 2011, Journal of the American College of Cardiology.
[26] T. Lisman,et al. Alterations in Fibrin Structure in Patients with Liver Diseases , 2016, Seminars in Thrombosis & Hemostasis.
[27] S. Diamond,et al. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. , 2013, Blood.
[28] S. Coughlin,et al. Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense. , 2015, Blood.
[29] W. Lam,et al. Factor XIII activity mediates red blood cell retention in venous thrombi. , 2014, Journal of Clinical Investigation.
[30] C. T. Ammollo,et al. Sepsis, thrombosis and organ dysfunction. , 2012, Thrombosis research.
[31] C. Samama. Fibrinogen Concentrates for Acquired Fibrinogen Deficiencies? , 2016, Seminars in Thrombosis & Hemostasis.
[32] N. Killeen,et al. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. , 1999, Nature.
[33] S. Diamond,et al. Blood Clots Are Rapidly Assembled Hemodynamic Sensors: Flow Arrest Triggers Intraluminal Thrombus Contraction , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[34] M. Mosesson. Update on antithrombin I (fibrin) , 2007, Thrombosis and Haemostasis.
[35] S. Kuroda,et al. Fibrin matrix provides a suitable scaffold for bone marrow stromal cells transplanted into injured spinal cord: A novel material for CNS tissue engineering , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.
[36] P. Grant,et al. Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication. , 2008, Journal of vascular surgery.
[37] J. Weisel,et al. Altered Fibrin Architecture Is Associated With Hypofibrinolysis and Premature Coronary Atherothrombosis , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[38] T. Nakabayashi,et al. Plasma soluble fibrin monomer complex as a marker of coronary thrombotic events in patients with acute myocardial infarction. , 2009, The Tohoku journal of experimental medicine.
[39] J. Zalewski,et al. Polyhedrocytes in intracoronary thrombi from patients with ST-elevation myocardial infarction. , 2015, International journal of cardiology.
[40] J. Degen,et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. , 1995, Genes & development.
[41] Marco M. Domingues,et al. The (Patho)physiology of Fibrinogen γ′ , 2016, Seminars in Thrombosis & Hemostasis.
[42] D. Fries,et al. Fibrinogen concentrate in dilutional coagulopathy: a dose study in pigs , 2014, Transfusion.
[43] M. Hanss,et al. A Database for Human Fibrinogen Variants , 2001, Annals of the New York Academy of Sciences.
[44] A. Ichinose,et al. Impaired clot retraction in factor XIII A subunit-deficient mice. , 2010, Blood.
[45] A. Casini,et al. Clinical Features and Management of Congenital Fibrinogen Deficiencies , 2016, Seminars in Thrombosis & Hemostasis.
[46] M. Freund,et al. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation. , 2009, Blood.
[47] M Galarza,et al. Role of EVICEL Fibrin Sealant to Assist Hemostasis in Cranial and Spinal Epidural Space: A Neurosurgical Clinical Study. , 2015, Surgical technology international.
[48] Rustem I. Litvinov,et al. Mechanisms of fibrin polymerization and clinical implications. , 2013, Blood.
[49] I. Ay,et al. Fibrin-targeted PET probes for the detection of thrombi. , 2013, Molecular pharmaceutics.
[50] R. Porte,et al. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. , 2010, Blood.
[51] H. Bianco-Peled,et al. The effect of structural alterations of PEG-fibrinogen hydrogel scaffolds on 3-D cellular morphology and cellular migration. , 2006, Biomaterials.
[52] A. Casini,et al. Congenital Fibrinogen Disorders: An Update , 2013, Seminars in Thrombosis & Hemostasis.
[53] J. Weisel,et al. A Structural and Dynamic Investigation of the Facilitating Effect of Glycoprotein IIb/IIIa Inhibitors in Dissolving Platelet-Rich Clots , 2002, Circulation research.
[54] D. Fries,et al. Role of fibrinogen in trauma-induced coagulopathy. , 2010, British journal of anaesthesia.
[55] A. Casini,et al. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management , 2015, Journal of thrombosis and haemostasis : JTH.
[56] A. Lebreton,et al. Natural history of patients with congenital dysfibrinogenemia. , 2015, Blood.
[57] I. Donati,et al. Adhesive and sealant interfaces for general surgery applications. , 2016, Journal of biomedical materials research. Part B, Applied biomaterials.
[58] S. Brennan,et al. Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin λ light chain , 2007, Haematologica.
[59] Peter Caravan,et al. Monovalent and bivalent fibrin-specific MRI contrast agents for detection of thrombus. , 2008, Angewandte Chemie.
[60] P. de Moerloose,et al. Congenital Fibrinogen Disorders , 2009, Seminars in thrombosis and hemostasis.
[61] R. Tiedt,et al. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. , 2007, Blood.
[62] C. Camargo,et al. Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. , 2010, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[63] E. Stępień,et al. Altered Fibrin Clot Structure/Function in Patients With Cryptogenic Ischemic Stroke , 2009, Stroke.
[64] N. Salamon,et al. CT and MRI Early Vessel Signs Reflect Clot Composition in Acute Stroke , 2011, Stroke.
[65] D. Fries. The early use of fibrinogen, prothrombin complex concentrate, and recombinant‐activated factor VIIa in massive bleeding , 2013, Transfusion.
[66] M. Liberatore,et al. Elastic behavior and platelet retraction in low- and high-density fibrin gels. , 2015, Biophysical journal.
[67] J. Hartwig,et al. Cell mechanics: Contracting to stiffness. , 2011, Nature materials.
[68] Peter Caravan,et al. Fibrin specific peptides derived by phage display: characterization of peptides and conjugates for imaging. , 2012, Bioconjugate chemistry.
[69] A. Stammers,et al. Soluble fibrin monomer complex and cardiopulmonary bypass. , 2009, The journal of extra-corporeal technology.
[70] P. Innerhofer,et al. The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. , 2013, Injury.
[71] Rennian Wang,et al. Fibrin, a scaffold material for islet transplantation and pancreatic endocrine tissue engineering. , 2015, Tissue engineering. Part B, Reviews.
[72] S. Diamond,et al. A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. , 2014, Blood.
[73] S. Kojima,et al. Clot retraction is mediated by factor XIII-dependent fibrin-αIIbβ3-myosin axis in platelet sphingomyelin-rich membrane rafts. , 2013, Blood.
[74] J. Martinez,et al. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. , 1978, The Journal of clinical investigation.
[75] J. Luyendyk,et al. Role of Fibrin(ogen) in Progression of Liver Disease: Guilt by Association? , 2016, Seminars in Thrombosis & Hemostasis.
[76] Richard T. Lee,et al. Custom Design of the Cardiac Microenvironment With Biomaterials , 2005, Circulation research.
[77] J. Weisel,et al. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. , 2002, Blood.
[78] G. Koenderink,et al. Factor XIII stiffens fibrin clots by causing fiber compaction , 2014, Journal of thrombosis and haemostasis : JTH.
[79] T. van der Poll,et al. A Short Contemporary History of Disseminated Intravascular Coagulation , 2014, Seminars in Thrombosis & Hemostasis.
[80] C. Doillon,et al. Angiogenic response of endothelial cells seeded dispersed versus on beads in fibrin gels , 2007, Angiogenesis.
[81] D. Witte,et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor αMβ2/Mac-1 is critical for host inflammatory response in vivo , 2004 .
[82] P. Grant,et al. Altered Fibrin Clot Structure in the Healthy Relatives of Patients With Premature Coronary Artery Disease , 2002, Circulation.
[83] J. Weisel,et al. The Platelet Integrin αIIbβ3 Differentially Interacts with Fibrin Versus Fibrinogen* , 2016, The Journal of Biological Chemistry.
[84] W. Lam,et al. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. , 2015, Blood.
[85] A. Casini,et al. Laboratory and Genetic Investigation of Mutations Accounting for Congenital Fibrinogen Disorders , 2016, Seminars in Thrombosis & Hemostasis.
[86] L. Armengou,et al. Fibrin deposits and organ failure in newborn foals with severe septicemia. , 2008, Journal of veterinary internal medicine.
[87] V. Schroeder,et al. Factor XIII: Structure and Function , 2016, Seminars in Thrombosis & Hemostasis.
[88] L Sedel,et al. A biodegradable fibrin scaffold for mesenchymal stem cell transplantation. , 2003, Biomaterials.
[89] M. Fatima,et al. Fibrin matrices: The versatile therapeutic delivery systems. , 2015, International journal of biological macromolecules.
[90] Peter Caravan,et al. EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. , 2008, Journal of the American Chemical Society.
[91] J. Davidson,et al. Wound-healing defects in mice lacking fibrinogen. , 2001, Blood.
[92] E. Stępień,et al. Hyperglycemia Is Associated With Enhanced Thrombin Formation, Platelet Activation, and Fibrin Clot Resistance to Lysis in Patients With Acute Coronary Syndrome , 2008, Diabetes Care.
[93] A. Słowik,et al. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. , 2010, Thrombosis research.
[94] S. Bates. D-Dimer Assays in Diagnosis and Management of Thrombotic and Bleeding Disorders , 2012, Seminars in Thrombosis & Hemostasis.
[95] H. Saito,et al. Advances in the understanding of MYH9 disorders , 2010, Current opinion in hematology.
[96] T. Haas,et al. The In Vitro Effects of Fibrinogen Concentrate, Factor XIII and Fresh Frozen Plasma on Impaired Clot Formation After 60% Dilution , 2008, Anesthesia and analgesia.
[97] K. Tomita,et al. Changes of the soluble fibrin monomer complex level during the perioperative period of hip replacement surgery , 2008, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.
[98] Mortimer Poncz,et al. T2 magnetic resonance: a diagnostic platform for studying integrated hemostasis in whole blood--proof of concept. , 2014, Clinical chemistry.
[99] L. Brass,et al. Shaping the platelet response to vascular injury , 2014, Current opinion in hematology.
[100] É. Katona,et al. Diagnosis and Management of Congenital and Acquired FXIII Deficiencies , 2016, Seminars in Thrombosis & Hemostasis.
[101] P. Cabrales,et al. Effects of Fibrinogen Concentrate After Shock/Resuscitation: A Comparison Between In Vivo Microvascular Clot Formation and Thromboelastometry* , 2013, Critical care medicine.
[102] D. Witte,et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. , 2004, The Journal of clinical investigation.
[103] Tai-De Li,et al. Mechanics and contraction dynamics of single platelets and implications for clot stiffening. , 2011, Nature materials.
[104] A. Wolberg,et al. Newly-Recognized Roles of Factor XIII in Thrombosis , 2016, Seminars in Thrombosis & Hemostasis.
[105] F. Peyvandi,et al. Fibrinogen replacement therapy for congenital fibrinogen deficiency , 2011, Journal of thrombosis and haemostasis : JTH.
[106] L. Rauova,et al. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. , 2014, Blood.
[107] J. Weisel,et al. Structural basis for the nonlinear mechanics of fibrin networks under compression. , 2014, Biomaterials.